There are direct and indirect costs associated with Alzheimer’s and other related dementia diseases policymakers have to consider. Direct costs, in this instance, are the medical and social/non-medical care costs related to dementia; on average, expenses included $273 per month…
The US Food and Drug Administration (FDA) recently approved a new drug under the trademark Aduhelm™ to treat Alzheimer’s disease. The drug, Aducanumab, is a therapeutic drug that clinically demonstrates a potential to delay further decline from Alzheimer’s disease and…
The elderly population in the United States is plagued by the use of multiple concurrent prescriptions. The more medications a person takes, the higher the risk of dangerous drug-drug interactions and increased possibility of inappropriate prescribing, adverse drug reactions, hospitalization,…
It is important for a condition like Alzheimer’s to have a strong power of attorney. Additionally, it is important to know that a good “basic” advance-directive document needs considerable supplementation when it comes to a dreadful illness like ALS –…